Prognostic Implications of N-terminal Pro-B Type Natriuretic Peptide and High-Sensitivity Cardiac Troponin T in EMPEROR-Preserved
JACC Heart Fail 2022 doi:S2213-1779(22)00302-X
This analysis aimed to evaluate associations between NT-proBNP and hs-cTnT and clinical outcomes. In this randomised, double-blind trial patients received placebo or empagliflozin. NT-proBNP and hscTnT were measured at baseline, with additional NT-proBNP data at Weeks 4, 12, 52, and 100.
Higher baseline NT-proBNP and hs-cTnT were associated with more comorbidities and worse heart failure severity. NT-proBNP increase from baseline was also associated with risk of cardiovascular death and hospitalisations for heart failure. The benefit of empagliflozin on cardiac outcomes and decline of renal function was preserved across the wide range of baseline NT-proBNP and hs-cTnT evaluated.